Fycompa
Neuralgia
Eisai Inc.Phase 2/3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
53 Active assets in the Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Ziauddin University | Phase 4 | A |
Capsaicin NeurogesX | Phase 3 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Ataturk University | Phase 4 | BBB |
Bxcl501 Universidad Juárez Autónoma de Tabasco | Phase 4 | BBB |
LIDOCAINE Pontificia Universidad Catolica de Chile | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Fycompa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →